|
 The shot, consisting of casirivimab and imdevimab antibodies
developed by Regeneron with financial help from the U.S. government,
also met all key secondary endpoints in the phase III trial with
4,567 participants, including reducing symptom duration to 10 days
from 14, Roche said.
Roche, which is making the drug at plants in California and which is
responsible for sales outside the United States, and Regeneron are
expecting hundreds of millions in sales in 2021 from the drug,
including $260 million alone to the U.S. government in the first
quarter.
"New infections continue to rise globally with over three million
reported cases last week, so this investigational antibody cocktail
may offer hope as a potential new therapy to high-risk patients -
particularly in light of recent evidence showing that casirivimab
and imdevimab together retain activity against key emerging
variants," Roche Chief Medical Officer Levi Garraway said.
[to top of second column] |
 Roche has said that it and
Regeneron can produce more than 2 million doses
annually.
The cocktail, which data previously showed has
been effective against variants, has emergency
approval in the United States, and has been
authorized in Europe for use in non-hospitalised
patients. Former U.S. President Donald Trump got
the treatment when he was infected with
COVID-19.
(Reporting by Michael Shields and John Miller;
editing by Brenna Hughes Neghaiwi)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content
 |
